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Abstract: 1C1m-Fc, an anti-tumor endothelial marker 1 (TEM-1) scFv-Fc fusion protein antibody,
was previously successfully radiolabeled with 177Lu. TEM-1 specific tumor uptake was observed
together with a non-saturation dependent liver uptake that could be related to the number of
dodecane tetraacetic acid (DOTA) chelator per 1C1m-Fc. The objective of this study was to verify
this hypothesis and to find the best DOTA per 1C1m-Fc ratio for theranostic applications. 1C1m-
Fc was conjugated with six concentrations of DOTA. High-pressure liquid chromatography, mass
spectrometry, immunoreactivity assessment, and biodistribution studies in mice bearing TEM-1
positive tumors were performed. A multi-compartment pharmacokinetic model was used to fit the
data and a global pharmacokinetic model was developed to illustrate the effect of liver capture and
immunoreactivity loss. Organ absorbed doses in mice were calculated from biodistribution results.
A loss of immunoreactivity was observed with the highest DOTA per 1C1m-Fc ratio. Except for
the spleen and bone, an increase of DOTA per 1C1m-Fc ratio resulted in an increase of liver uptake
and absorbed dose and a decrease of uptake in tumor and other tissues. Pharmacokinetic models
correlated these results. The number of DOTA per antibody played a determining role in tumor
targeting. One DOTA per 1C1m-Fc gave the best pharmacokinetic behavior for a future translation of
[177Lu]Lu-1C1m-Fc in patients.
Keywords: TEM-1; fusion protein antibody; DOTA conjugation; 177Lu radiolabeling; biodistribution;
tumor/liver ratio; theranostic
1. Introduction
Radiolabeled monoclonal antibodies (mAbs) have been actively investigated for thera-
nostic applications [1]. The radiolabeling of a mAb with a metallic radionuclide, generally
involves the use of suitable bifunctional chelating agents (BFCAs) with high metal-chelate
stability constants. BFCAs are designed to stably coordinate the radionuclide and to allow
a covalent attachment to protein functional groups [2,3]. Most protocols used to conjugate
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antibodies with BFCAs are not site-specific and result in a variable number of BFCAs
per antibody, depending on experimental conditions and antibodies themselves. With
non-site-specific processes, the average number of BFCA attached per antibody depends
upon the molar ratios of antibody and BFCA used for the conjugation as well as on the
reaction conditions employed for the conjugation [4].
Dodecane tetraacetic acid (DOTA) derivatives, which are hydrophilic macrocyclic lig-
ands, have been used as the most popular BFCAs for the development of radio-lanthanide-
labeled mAbs [5].
An increasing chelator-to-antibody ratio often allows to improve the specific activity
of the radiolabeled compound. Nevertheless, the hydrophilicity/lipophilicity, the charges
of the conjugate, and consequently the pharmacokinetics of the antibody can be modified
by the conjugation of hydrophilic DOTA chelator [4].
Authors showed that an increasing number of DOTA per antibody resulted in a
decrease of the non-specific liver uptake [6,7]. The provided explanation was the reduction
of the isoelectric point (pI) correlated to the increase of the negative charge given by the
DOTA chelator resulting in important repulsion between the lipid bilayer and the conjugate.
However, the impact of the increasing number of negative charges on the biodistribution
was unclear. On the opposite, some groups observed a rapid blood clearance, a decrease
of the tumor uptake and an increase of the hepatic uptake with high number of chelators
conjugated to an antibody [8,9]. The conjugation with a high number of DOTA can alter
the immunological properties of the antibody due to the possibility of DOTA to bind the
variable domains of the antibody, involved in antigen targeting [4]. Moreover, a high
number of chelators per antibody could change the tumor targeting pharmacokinetic due
to the uptake of the conjugate by the reticuloendothelial system in liver and spleen [1].
The biodistribution of radiolabeled conjugated antibody is determined by the chelator
to antibody ratio but also by many different parameters of the radionuclide such as the size,
the chelation geometry and the coordination number. It would be necessary to optimize
the conjugate regarding these criteria [6,8].
In this study, 1C1m-Fc, a scFv-Fc fusion antibody constructs which bind to murine and
human tumor endothelial marker 1 (TEM-1) was conjugated to p-SCN-Bn-DOTA chelator.
After conjugation 1C1m-Fc was radiolabeled with 177Lu. This radionuclide, which is a γ
and β− emitter allowing theranostic approach.
TEM-1, also named endosialin/CD248, is a 80.9 kDa type I cell surface transmembrane
protein of the C-lectin receptor family [10–12] implicated in development, vascular cell
adhesion and migration, neoangiogenesis, and tumor progression [13,14]. TEM-1 over
expression correlates with a poor patient prognosis and a tumor aggressiveness [15,16].
Its high expression on the tumor vasculature of several solid human cancers, with
limited expression in normal adult tissue, makes TEM-an ideal target for theranostic
applications [17,18].
Our previous study showed that [177Lu]Lu-1C1m-Fc could prove as a potentially
useful and safe tool for theranostic applications [19]. In these experiments, while the
TEM-1 positive uptake was specific, we also observed an important liver uptake that was
not saturation-dependent. Our hypothesis for this phenomenon was the influence of the
number of DOTA on the biodistribution.
The conjugation of antibodies and antibody fragments with chelator plays a significant
role in determining the success of tumor targeting employing radiolabeled antibodies [4,8].
Therefore, the goal of this study was to evaluate the effect of coupling an increasing number
of DOTA per 1C1m-Fc on the pharmacokinetic behavior, immunoreactivity, and dosimetry
of the radiolabeled antibody complex to develop an optimal radiolabeled 1C1m-Fc suitable
for theranostic application.
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2. Materials and Methods
2.1. Fusion Protein Antibody
Complete description of the single-chain variable fragment (scFv) 1C1m-Fc (Molecular
Weight = 106196.8 Da) was done in Delage et al [19] and Fierle et al [20]. Briefly, this fusion
protein antibody recognizes efficiently human and murine TEM-1 antigen over expressed
in tumor cells and in SK-N-AS cell line that was chosen to develop the animal model.
2.2. Cell Lines
The human neuroblastoma SK-N-AS (TEM-1 positive) cell lines was purchased from
American Type Culture Collection (ATCC, Manassas, VA, USA).
SK-N-AS cells were cultured in DMEM (Thermo Fisher Scientific, Waltham, MA,
USA) supplemented with 0.1 mM Non-Essential Amino Acids (Thermo Fisher Scientific,
Waltham, MA, USA), 10% fetal bovine serum (FBS, Thermo Fisher Scientific, Waltham,
MA, USA) and 1% penicillin/streptomycin (Thermo Fisher Scientific, Waltham, MA, USA).
Cells were incubated at 37 ◦C in a humidified atmosphere at 5% CO2.
2.3. Conjugation
Antibody concentration was measured at 280 nm using a spectrophotometer (Nan-
oDrop Lite, Thermo Fisher Scientific, Waltham, MA, USA). To obtain conjugates with
increasing ligand-to-antibody ratios, 6 concentrations of p-SCN-Bn-DOTA (Macrocyclics,
Plano, TX, USA; MW: 551.6) from 5 to 50 equivalents were used.
Prior to the coupling procedure, the 1C1m-Fc was conditioned in carbonate buffer
0.2 M pH 9.0 by ultrafiltration on a 50 kDa ultrafiltration membrane (Amicon Ultra, 0.5 mL,
50 kDa, Merck, Darmstadt, Germany). To 1 mg (9.4 nmol; 200 µL) of 1C1m-Fc was added
a calculated quantity of a 25.9 mg/mL (47 µmol/mL) p-SCN-Bn-DOTA solution in an
extemporaneously made mixture of 10% DMSO (v/v) in the same carbonate buffer. The
BFCA-to-1C1m-Fc ratios used were 5, 10, 20, 30, 40, and 50.
Antibody coupling solutions were incubated for 1 h at 37 ◦C and the conjugated
antibodies were washed by four ultrafiltrations using PBS pH 7.4 before performing high-
pressure liquid chromatography (HPLC) to assess integrity of the conjugates. Conjugated
fusion protein antibodies were subsequently stored between 2 and 8 ◦C.
2.4. Mass Spectrometry Analysis
Mass spectrometry (MS) analysis was performed using a Q Exactive HF Orbitrap
(Thermo Fisher Scientific, Waltham, MA, USA) and separation was done using a MAbPAC
SEC-1 column, (Thermo Fisher Scientific, Waltham, MA, USA) with a mobile phase of
ammonium acetate 50 mM pH 7.0 at 0.3 mL/min as previously described [19]. After
deconvolution of the mass spectrometry spectra, the drug-to-antibody ratio (DAR) is
calculated using the formula:
Σ(n*Int)/Σ (Int)
where n = number of attached molecules for this peak and Int = intensity of the peak.
2.5. Radiolabeling
The radiolabeling was optimized in acetate buffer 0.4 M pH 5.6 with respectively
500 pmol of DOTA-conjugated 1C1m-Fc and 20 MBq of 177Lu without carrier in aqueous
0.04 M HCl solution (EndoleucineBeta 40 GBq/mL, ITM, Garching bei München, Germany).
After 1 h incubation time at 37 ◦C, the radiochemical purity was determined by instant thin
layer chromatography (iTLC) in citrate buffer 0.1 M pH 5.0.
The release criterion was radiochemical purity over 95%.
If necessary, the excess of 177Lu was removed with one to three ultrafiltrations on
50 kDa membrane (Amicon Ultra, 0.5 mL, 50 kDa, Merck, Darmstadt, Germany) in acetate
buffer 0.4 M pH 5.6.
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2.6. Purity and Stability
Chemical purity of 1C1m-Fc was tested using HPLC and gel electrophoresis as de-
scribed in Delage et al. [19]. Stability of the fusion protein was evaluated at 3, 6, and 12
months after his production by HPLC only. Radiochemical purity after antibody radiola-
belling was assessed by TLC on iTLC-SG at 24 and 48 h.
2.6.1. HPLC
As described in Delage et al. [19], HPLC analyses were done using an Ultimate 3000
SD System (Thermo Fisher Scientific, Waltham, MA, USA) and a GabiStar radiodetector
(Elysia-Raytest GmBH, Straubenhard, Germany). A size exclusion chromatography was
performed using phosphate buffer pH 6.8 as solvent and a 200 kDa size exclusion column
(XBridge protein BEH, Waters, Baden-Dättwil, Switzerland). Each chromatography profile
was analyzed at 280 nm.
2.6.2. iTLC
TLC on iTLC-SG (Agilent Technologies, Folsom, CA, USA) was performed in citrate buffer
0.1 M pH 5.0. Using these conditions, unbound 177Lu is complexed by the solvent and migrates
at retention factor (Rf ) = 1 while charged [177Lu]Lu-1C1m-Fc remains at Rf = 0.
2.7. In Vitro Characterization of Immunoreactivity
Immunoreactive fraction assessment was done as in Delage et al. [19]. Briefly, each
coupled 1C1m-Fc-DOTA and native 1C1m-Fc were evaluated by Lindmo assay [21]. An in-
creasing number of SK-N-AS cells (0.25–8 × 106) were incubated with a fixed concentration
of radiolabeled 1C1m-Fc (0.07 µg/mL; 0.659 pmol/mL). A fusion protein antibody excess of
100-fold concentration was used to evaluate the non-specific binding. The immunoreactive
fraction was calculated by extrapolation to an infinite cells number by fitting the curve
with a non-linear regression method (Graphpad Prism 8.0, 2018 GraphPad Software, San
Diego, CA, USA).
2.8. In Vivo Characterization
2.8.1. Murine Xenograft Model
All animal experiments were performed in accordance with the Swiss legislation for
the care and use of laboratory animals under the license VD-2993 (09/2018) delivered after
approbation by the Veterinarian Office of the canton of Vaud and the ethics committee.
Female Balb/C nude mice (Charles River Laboratories, Wilmington, MA, USA) be-
tween 8 and 10 weeks were subcutaneously grafted with 3.00 × 106 SK-N-AS cells as
described in Delage et al. [19]. Mice were assigned to the experimental groups when the
tumor reached 5–10 mm diameter size.
2.8.2. Biodistribution Studies
To define the impact of the conjugation on the biodistribution, a mixture of 2.5 µg
(23.5 pmol) of [177Lu]Lu-1C1m-Fc conjugated with respectively 1, 2.5, 3, 6, 8, and 11 DOTA
per 1C1m-Fc and 47.5 µg (447.3 pmol) of native unlabeled 1C1m-Fc was injected into the
lateral tail vein of the mice (n = 3) without anesthesia. The volume for all the injections was
100 µL and sodium chloride 0.9% (B.Braun, Sempach, Switzerland) was used to perform
the dilution. The injected solution was not filtered.
The average weight of animals was 18.4 ± 1.8 g. The dose of 50 µg (470 pmol) of
antibody has been selected from our previous study [19].
Mice were sacrificed by CO2 inhalation 24 h after radiolabeled antibody injection.
Blood was collected by exsanguination. Organs and tumors were weighted after drying
and them and counted with a gamma counter (AMG Automatic Gamma Counter, Hidex,
Turku, Finland).
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For the [177Lu]Lu-1C1m-Fc conjugated with 1 and 3 DOTA, complementary time
points have been added for the biodistribution, and animals (n = 3) were euthanized 4, 24,
48, 72 h, and 6 days after injection.
Results were expressed as a percentage of injected activity (IA) per gram of tissue
(%IA/g).
2.8.3. Pharmacokinetic Modeling
Data were expressed as percent injected activity per gram of tissues. A multi- com-
partment pharmacokinetic model was used in which the injected antibody was distributed
from a central compartment, representing the blood, into peripheric compartments cor-
responding to all investigated organs plus an additional compartment representing all
uncounted tissues. Tissue contents were calculated as the content of the tissue compartment
plus a fraction of blood activity. This is equivalent to consider fast and a slow distribution
compartments as in similar models [22] given that the fast kinetics cannot be accounted
for from data collected over 6 days. The biodistribution kinetics for all studied tissues
were modelled for the 1 and 3 DOTA per 1C1m-Fc using a software package developed in
Arronax Laboratory available upon request (www.arronax-nantes.fr). This software pack-
age, similar to and validated by comparison with WinSAAM [23], allows pharmacokinetic
modelling directly from a Microsoft Excel worksheet. Differential equations were solved
numerically using the Chu–Berman algorithm [24]. Variable parameters were estimated
using the non-linear weighted least squares Levenberg–Marquardt algorithm.
It was then assumed that the rate of liver uptake was proportional to the number of
DOTA per antibody and that the rates of uptake into tumor and uterus (a normal tissue
expressing low amounts of antigen) increased linearly with the immunoreactivity. Con-
versely, the rates of spleen and bone uptake were assumed to decrease linearly with the
immunoreactivity. Then all available biodistribution data, at all time-points for 1 and 3
DOTA per 1C1m-Fc, and at 24 h after injection for the other conjugates were fitted simulta-
neously using a single set of kinetic parameters. The model is described in Appendix A
(Figures A1–A3 and Table A1.).
2.8.4. Murine Dosimetry
Estimated absorbed doses to organs were based on the biodistribution results of mice
bearing TEM-1 positive tumor injected with [177Lu]Lu-1C1m-Fc conjugated with 1 DOTA.
Considered source organs were liver, kidneys, lungs, spleen, heart (cardiac muscle), blood
pool, stomach, small intestine, colon, ovaries, uterus, urinary bladder, salivary glands,
and the total body. The reminder was obtained by subtraction of the signal measured in
source organs from the total body. For each mouse at each time point, the activity in each
source organ and the remainder was normalized by the total injected activity to obtain the
normalized injected activity (nA). For each source organ at each time point, an average nA
value was obtained ±SD.
For all source organs with the exception of stomach, uterus, salivary glands and
the urinary bladder, the normalized time activity curves (nTACs) were fitted with bi-
exponential functions using the kinetic module of OLINDA/EXM 2.1 (HERMES Medical
Solution AB, Stockholm, Sweden). Time-integrated activity coefficients (TIACs) were
derived by analytical time-integration of fitted source organ nTACs obtained with the
average nA, nA + SD and the nA − SD values, respectively.
The nTACs for stomach, uterus, salivary glands, urinary bladder and the tumor were
not conveniently fitted by monotonically decreasing bi-exponential functions. For these
tissues, the TIAC was obtained by trapezoidal integration using Matlab software (Release
2019b, The MathWorks, Inc., Natick, MA, USA), between t = 0 and t = 6 days, whereas a
mono-exponential analytical integration to infinity was calculated after the last measure
(t > 6 days) considering the 177Lu physical decay constant.
Finally, source organ TIACs were entered into the OLINDA/EXM® 2.1 software kinetic
module for organ absorbed dose estimates considering the 25 g murine model where the
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phantom source organ masses were adjusted to the average organ masses obtained from
the mice population considered for the dosimetry experiment. In this process, the TIAC of
the ovaries, uterus and the salivary glands was part of the remainder of the body.
A specific absorbed dose estimation was obtained for ovaries, uterus and the salivary
glands. These organs, in fact, exhibit an important specific tracer uptake, but were not
among the source/target organs available in the murine model of OLINDA/EXM 2.1
software. For these organs, the absorbed dose estimation was obtained using the sphere
model of OLINDA/EXM 2.1 where the average organ TIAC and the average organ mass
were applied.
Estimated absorbed doses to tumor and selected organs based on the biodistribution
results on TEM-1 positive tumor bearing mice injected with [177Lu]Lu-1C1m-Fc conjugated
respectively with 1 and 3 DOTA were compared. The dosimetry with the 3 DOTA conjuga-
tion was obtained from our previous study [19]. The selected organs were the liver, the
lungs, the kidney, the spleen and the uterus.
2.9. Statistics
The data are expressed as mean ± SD (standard deviation) or SEM (standard error
to the mean). Significant differences between immunoreactive fractions were analyzed
by ordinary one-way Anova using the Turkey’s multiple comparisons method. Data
from biodistribution studies were analyzed by an unpaired, 2-tailed Student t test with a
correction for multiple comparison using the Holm–Sidak method (α = 0.05). Correlation
between the tumor/liver ratio and the ratio of DOTA per 1Cm-Fc were analyzed with
a Spearman test. Curve-fitting and statistical analyses were conducted using Prism 8.0
(GraphPad Software, San Diego, CA, USA). Pharmacokinetics analyses were performed
with Kinetics software.
3. Results
3.1. Conjugation and Radiolabeling
1C1m-Fc was conjugated with six concentrations of DOTA between 5 and 50 equiva-
lents. The number of DOTA was estimated for each concentration (Table 1, Figure S1) and
was between 1 and 11 DOTA.
Table 1. Estimated number of DOTA per 1C1m-Fc based on mass spectrometry and purity analyses
of the conjugates from 5 to 50 equivalents (eq) of DOTA. The estimated DAR is calculated using the
formula: Σ(n*Int)/Σ (Int), where n = number of attached molecules for this peak, Int = intensity of
the peak.





Unmodified 1C1m-Fc 108,394 NA (not applicable) 97.4%
DOTA (- HCl-H2O) 551 NA NA
1C1m-Fc 5 eq DOTA 108,395–108,985 1 95.6%
1C1m-Fc 10 eq DOTA 108,986–110,758 2.5 96.2%
1C1m-Fc 20 eq DOTA 109,496–111,746 3 95.7%
1C1m-Fc 30 eq DOTA 110,755–113,117 6 96.9%
1C1m-Fc 40 eq DOTA 111,746–114,664 8.5 96.2%
1C1m-Fc 50 eq DOTA 113,711–116,068 11 96.8%
1C1m-Fc and its conjugates were analyzed by HPLC. The purity of conjugated anti-
bodies is reported in Table 1. The HPLC profiles, the stability of the native and conjugated
fusion protein antibody, and the stability in serum of [177Lu]Lu-1C1m-Fc were given in our
prior publication [19].
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The release criteria for the radiochemical purity (RCP) evaluated by TLC was more
than 95%. To reach this criterion with antibodies modified with 1 and 2.5 DOTA, ultrafiltra-
tion on amicon membrane (Amicon Ultra, 0.5 mL, 50 kDa, Merck, Darmstadt, Germany)
was used. HPLC was not used in this study to evaluate the RCP as this test was done in
our previous study [19] and the results were similar to that obtained using TLC.
3.2. Immunoreactive Fraction
The immunoreactivity following the radiolabeling was assessed by Lindmo assay
(Table 2; Figure S2).
Table 2. Radioimmunoreactive fraction results for [177Lu]Lu-1C1m-Fc conjugated with 1 to 11 DOTA.
Number of DOTA per 1C1m-Fc Immunoreactivity (%) ± SEM
1 85.1 ± 1.3
3 86.2 ± 2.7
6 87.5 ± 1.0
8.5 78 ± 1.4
11 24 ± 1.7
For validation tests comparative immunoreactivity assessment with incubation at
37 ◦C and 4 ◦C were carried out and the results obtained showed no difference at 3 h.
Furthermore, internalization results of 1C1m-Fc radiolabeled with 125I have been published
and showed that the rate of internalization was quite slow suggesting that the antibody does
not trigger the rapid migration of TEM-1 from the cell surface [25]. The immunoreactivity,
that was 85.1 ± 1.3, 86.2 ± 2.7, 87.5 ± 1.0, and 78 ± 1.4% for 1, 3, 6, and 8.5 DOTA,
respectively suggesting that it was not affected by the conjugation up to 8.5 DOTA (Turkey’s
multiple comparisons test, p > 0.068, n = 17).
On the other hand, a significative loss of immunoreactivity to 24 ± 1.7% was obtained
with the highest number of BFCA (11 DOTA per fusion protein antibody) compared to the
others ratios (Turkey’s multiple comparisons test, p < 0.0001, n = 17).
3.3. In Vivo Characterization
3.3.1. Biodistribution Study at 24 h
The biodistribution of [177Lu]Lu-1C1m-Fc conjugated with 1, 2.5, 3, 6, 8, and 11 DOTA
units respectively was performed 24 h after injection.
A decrease of tumor uptake was observed with the 1C1m-Fc conjugated with more
than 3 DOTA (18.8 ± 1.5% IA/g up to 3 DOTA to 5.3 ± 1.6% IA/g for 11 DOTA). In parallel,
an accelerated blood clearance was observed with the increasing number of chelator and
the radiotracer circulating in the blood at 24 h varied from 10.2 ± 0.6% for 1 DOTA per
antibody to 2.2 ± 0.7% for 11 DOTA per antibody (Figure 1a).
An inverse correlation of the tumor/liver ratio was observed with the increasing
number of DOTA per antibody, from 2 with 1 DOTA per antibody to 0.15 with 11 DOTA
per antibody (Spearman test, rho = −0.99, p < 0.0001) (Figure 1b).
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Figure 1. (a) Biodistribution at 24 h of [177Lu]Lu-1C1m-Fc conjugated with 1 to 11 DOTA in Balb/c nu mice bearing TEM-1
positive tumor. Data are shown as mean ± SD. (b) Ratio between the tumor and the liver uptake at 24 h with respect to the
number of DOTA per [177Lu]Lu-1C1m-Fc in Balb/c mice bearing TEM-1 positive tumor. Spearman test gives a rho = −0.99,
p < 0.0001.
3.3.2. Complementary Analyses for 1C1m-(DOTA)1 and 1C1m-(DOTA)3
For the [177Lu]Lu-1C1m-Fc conjugated with 1 and 3 DOTA, complementary time
points have been added for the biodistribution and animals were euthanized at 4, 24, 48,
72 h, and six days after injection.
The uptake in TEM-1 positive tumors was unchanged between the two groups. How-
ever, in the case of [177Lu]Lu-1C1m-Fc conjugated with 1 DOTA, the non-specific uptake
in the liver was lower than that observed with 3 DOTA conjugated at 24 and 48 h, where
p = 0.02 and 0.01 (unpaired t-test, n = 3) respectively (Figure 2a,b).
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Figure 2. Biodistribution of [177Lu]Lu-1C1m-Fc in Balb/c nu mice bearing TEM-1 positive tumor, (a) conjugated with 1
DOTA; (b) conjugated with 3 DOTA. Data are shown as mean ± SD, (n = 3).
3.3.3. Pharmacokinetic Modeling
Kinetics with 1C1m-Fc conjugated respectively with 1 and 3 DOTA were satisfactorily
fitted by the model (Figure S3a,b).
Tissues showing highest uptake were the tumor and the uterus and, for 1C1m-Fc
conjugated with 3 DOTA, the liver. For the liver, the estimated uptake rate constants of the
1C1m-Fc conjugated with 3 DOTA was 3.5 times that of the 1 DOTA, in line with the higher
uptake. The wash-out rate was relatively fast for the 3 DOTA, but, because of a single
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high value at six days, was fitted to 0 for the 1 DOTA, preventing further comparison. The
differences in estimated rate constants and tissue blood contents for the other tissues were
hard to interpret because of relatively high SD on measurements, particularly for uterus
and bone.
As expected, the simultaneous fit (Figure S4) represented less closely the biodistribu-
tion data, but the general shape and trends were conserved.
More interestingly, the trends in 24 h biodistributions for the six different concentra-
tions of DOTA were well replicated (Figure 3).
Figure 3. Comparison between the results obtained by biodistribution (in grey) and pharmacokinetic modeling (in red) at
24 h for [177Lu]Lu-1C1m-Fc conjugated with 1 to 11 DOTA in Balb/c nu mice bearing TEM-1 positive tumor.
The increased liver uptake at higher numbers of DOTA effectively decreases the
amount of circulating [177Lu]Lu-1C1m-Fc and consequently the amount of [177Lu]Lu-
1C1m-Fc in most of other organs. The loss of immunoreactivity explains the decrease
of the TEM-1 specific uptake in the tumor and the uterus, especially at the two highest
DOTA per antibody ratios. Finally, the increase of the spleen and bone uptake at the
highest concentrations of DOTA was accounted by a higher uptake of non-immunoreactive
[177Lu]Lu-1C1m-Fc. This condition was simulated by a linear decrease of the spleen uptake
rate with immunoreactivity.
3.3.4. Murine Dosimetry
Extrapolated organ absorbed doses for mice derived from the injection of [177Lu]Lu-1C1m-
Fc conjugated with 1 DOTA are given in Table 3. The organs receiving the highest absorbed
dose was the uterus (1.83 ± 0.14 Gy/MBq), followed by the liver (1.79 ± 0.13 Gy/MBq), the
stomach wall (1.66 ± 0.08 Gy/MBq) and the kidneys (1.32 ± 0.05 Gy/MBq). The total body
dose was 0.55 ± 0.04 Gy/MBq and the tumor dose was 2.53 ± 0.25 Gy/MBq. The tumor-to-liver
absorbed dose ratio was 1.41.
The absorbed doses for tumor, liver, kidneys, lungs, uterus and bladder were compared
between [177Lu]Lu-1C1m-Fc conjugated respectively with 1 DOTA and 3 DOTA (Table 4).
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Table 3. Considered organ masses, estimated source organ TIAC and organ absorbed doses [177Lu]Lu-1C1m-Fc. Organ masses of
the 25g mouse model of Olinda/EXM 2.1 were used for: brain, thyroid, testes, skeleton, pancreas and the heart content, for all other
organs we used the experimental mean masses.
Organ Mean Organ Mass (g) TIAC (MBq·h/MBq) Abs. Dose (mGy/MBq)
Mean SD Mean SD
Brain t 0.50 - - 4.08 × 102 2.70 × 101
Large intestine s,t 0.78 1.98 0.33 7.03 × 102 8.10 × 101
Small intestine s,t 1.20 3.33 0.25 5.77 × 102 4.00 × 101
Stomach s,t 0.26 0.77 0.03 1.66 × 103 8.00 × 101
Heart t 0.11 0.48 0.06 1.10 × 103 1.50 × 102
Heart content s 0.2 1.84 0.35
Kidneys s,t 0.31 3.37 0.13 1.32 × 103 5.00 × 101
Liver s,t 1.13 21.49 1.72 1.79 × 103 1.30 × 102
Lungs s,t 0.15 1.03 0.31 9.83 × 102 2.07 × 102
Pancreas t 0.30 4.41 × 102 2.80 × 101
Skeleton t 2.20 4.18 × 102 2.80 × 101
Spleen s,t 0.10 1.06 0.03 1.18 × 103 1.00 × 102
Ovaries s,* 0.04 0.41 0.08 7.42 × 102 9.90 × 101
Uterus s,* 0.11 2.54 0.24 1.83 × 103 1.40 × 102
Testes t 0.16 4.09 × 102 2.60 × 101
Thyroid t 0.01 4.09 × 102 2.70 × 101
Salivary glands s,* 0.11 0.75 0.02 5.41 × 102 1.70 × 101
Urinary Bladder s,t 0.02 0.17 0.01 5.34 × 102 3.70 × 101
Total Body s,t 18.44 111.08 6.54 5.49 × 102 3.80 × 101
Tumor s,* 0.21 6.81 0.71 2.53 × 103 2.50 × 102
(S) Source organs with experimentally derived TIAC; in walled organs, the TIAC included the content. (t) Target organs available for the 25g
mouse model in OLINDA/EXM 2.1 from which mean absorbed dose was obtained; in walled organs, the absorbed dose is computed for
the wall. (*) Absorbed dose computed with the sphere model of OLINDA/EXM 2.1. The organ %IA/g decay corrected and the normalized
time-activity curves for the considered source organs are presented in the Supplementary Materials (respectively Figures S5 and S6).
Table 4. Mouse dosimetry comparison between [177Lu]Lu-1C1m-Fc conjugated with 1 or 3 DOTA.
The selected organ of interested are the TEM-1 positive tumor, the liver, the kidneys, the lungs, the
spleen and the uterus.
Source Organ Absorbed Dose (mGy/MBq)
1 DOTA 3 DOTA
Tumor SK-N-AS 2.53 × 103 ± 2.50 × 102 1.82 × 103 ± 3.23 × 102
Liver 1.79 × 103 ± 1.30 × 102 2.23 × 103 ± 3.99 × 102
Kidneys 1.32 × 103 ± 5.00 × 101 7.05 × 102 ± 6.03 × 101
Lungs 9.83 × 102 ± 2.07 × 102 5.39 × 102 ± 1.30 × 102
Spleen 1.18 × 103 ± 1.00 × 102 1.20 × 103 ± 7.51 × 101
Uterus 1.83 × 103 ± 1.40 × 102 1.50 × 103 ± 5.15 × 102
Tumor/Liver ratio 1.4 0.8
The tumor/liver absorbed dose ratio increased from 0.8 for the [177Lu]Lu-1C1m-Fc
conjugated to 3 DOTA to 1.4 for the [177Lu]Lu-1C1m-Fc conjugated to 1 DOTA. The non-
specific uptake in the kidneys, the lungs and the specific uterus uptake was higher with
the fusion protein conjugated with 1 DOTA.
4. Discussion
Because of its expression across many tumors, its low expression in normal tissues and
accessibility from the vascular circulation, TEM-1 is emerging as an interesting biomarker
for theranostics [26]. Several IgG antibodies targeting the lectin-like domain of TEM-1 have
already been developed for oncological application [13,26].
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Given the very short half-life and the relative in vivo instability of monovalent scFv
antibody fragments, a bivalent Fc-fusion protein based on a novel single chain antibody,
1C1m-Fc, has been synthesized. The fusion of scFvs to the IgG Fc constant domains adds
significant size, avidity and stability to the targeting moiety and would be expected to lead
to improved blood pharmacokinetics.
Our previous study showed the relevance of this novel fusion protein antibody radi-
olabeled with 177Lu for a theranostic approach [19]. The aim of the present work was to
study the effect of the DOTA conjugation on the immunoreactivity, the pharmacokinetics
and the dosimetry of [177Lu]Lu-1C1m-Fc.
Six different conjugates were obtained by incubating 1C1m-Fc with several molar ratio
of DOTA respectively: 5, 10, 20, 30, 40, and 50 equivalents of DOTA. All the conjugates were
analyzed by mass spectrometry and the number of DOTA moieties attached per 1C1m-Fc
were respectively 1, 2.5, 3, 6, 8.5, and 11. Even if the HPLC profile of these conjugates was
similar, they are expected to have different pharmacokinetics behavior.
Radiolabeling was performed with 177Lu to obtain formulation with a RCP of more
than 95%. The immunoreactivity following the radiolabeling was assessed by Lindmo assay.
The immunoreactivity was not affected by the conjugation up to 8.5 DOTA. Nevertheless,
a significative loss of the immunoreactivity was observed with 11 DOTA (IR = 24%).
Several studies indicated that immunoreactivities of radiolabeled antibody were getting
compromised with the increase in the number of BFCA attached per antibody moieties.
Indeed, conjugation of the variable chain can weaken or abrogate antigen binding which in
turn decreases the efficacy of the targeting of the immunoconjugate [27,28]. Wangler et al.
demonstrated that the size of the conjugated dendritic structure does not significantly
influence the immunoreactivity of the antibodies over a wide molecular weight range,
whereas the number of derivatization sites is the major factor that determines the binding
affinity of the conjugates [29]. Grunberg et al. and Fischer et al. [28,30] showed that
an enzymatic conjugation leads to immunoconjugates with a uniform and well-defined
substitution only on the heavy chain. With this technique increasing numbers of DOTA
moieties was accompanied by an increasing specific activity of the immunoconjugates
when labeled with 177Lu. The advantage of the high specific activity was not counteracted
by the simultaneous decrease of immunoreactivity. A site-specific enzymatic conjugation
to the constant region could be better by less altered radio-immunoreactivity [31].
A biodistribution study of [177Lu]Lu-1C1m-Fc conjugated with all the DOTA conju-
gates was performed. A significant decrease of the tumor uptake was observed 24 h after
injection with the 1C1m-Fc conjugated with more than 3 DOTA. This time point has been
chosen as we have seen in our previous study that it was the most informative one [19].
This behavior could be attributed to the increased hydrophilicity of [177Lu]Lu-1C1m-Fc
with the number of DOTA attached to the molecule. Indeed, highest number of hydrophilic
DOTA or chelator has been described to exhibit a rapid blood clearance resulted in an
increasing uptake in the liver [4,8,32,33], but the mechanism was unclear. Knogler et al.
proposed that it can be due to the conformational change of the backbone structure of the
antibody induced by over-coupling, resulting in a rapid sequestration by the reticuloen-
dothelial system in the liver but invalidated this hypothesis as no difference was found in
CD spectra between substituted and unsubstituted antibody [1,8].
On the other hand, it has been suggested that the negative charge conferred to the
antibody by DOTA conjugation results in a reduced isoelectric point (pI), causing a net
repulsion between the molecule and the phospholipid bilayer, reducing the hepatobiliary
excretion or the hepatic uptake [6,7]. Several publications indicate that a decrease of the
liver uptake could be observed with negatively charged peptides or antibodies derivates
compared to neutral or positively charged conjugated variants [9,34–36]. General approach
described to improve imaging contrast in the liver include increasing the hydrophilicity via
a hydrophilic chelator or linker, modifying the positioning and composition of potential
purification tags or increasing negative charge [34–36]. These observations differ to the
results of our experiment. However, it is relevant to note that, in these publications,
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different types of chelates grafted on same vector were compared but with the same
chelate-to-vector ratio. The impact of the different chelators on biodistribution and imaging
contrast was assessed. On the contrary, we have studied the effect of a same chelate, DOTA,
with various antibody-to-ligands ratios. This difference in the methodology could explain
the different results.
Complementary analysis has been added for 1 and 3 DOTA to ensure the consistency
of the model. The biodistribution of the radiolabeled antibody was well described using a
multi-compartment model that showed a clear increase in the liver uptake rate between 1
and 3 DOTA per antibody. To further rationalize this effect, all available data were fitted
simultaneously using the same compartment model, assuming linear relationships between
the liver uptake rate constant and the number of DOTA and between the tumor and uterus
uptake rate constants and the immunoreactivity. Finally, uptake in the spleen and the bone
was assumed to increase with the loss of immunoreactivity. Linear relationships were
selected as first order approximations. This model was consistent with the observed data:
increased liver uptake at higher DOTA-substitution ratios depletes the circulating antibody
and the amount of antibody found in all tissues. In addition, the loss of immunoreactivity
further decreases the specific absorption into the tumor and uterus. Assuming a faster
uptake of non-immunoreactive antibody in spleen and bone accounts for the high uptake
seen with the 11-DOTA antibody. While a model cannot be considered a proof, this
one shows that simple hypotheses may explain the observations made in biodistribution
experiments.
We decided to evaluate the extrapolated organ absorbed doses for mice derived from
the injection of [177Lu]Lu-1C1m-Fc conjugated with the two lowest concentrations of DOTA,
namely 1 and 3 DOTA per fusion protein antibody as they gave the best specific/non-
specific uptake ratio in the biodistribution study. Organ receiving the highest doses were
liver and uterus. Two other anti TEM-1 antibodies, 78Fc labeled with 111In and Morab-004
labeled with 124I showed similar results in these organs [26,37].
The tumor/liver absorbed dose ratio increased from 0.8 for the [177Lu]Lu-1C1m-
Fc conjugated to 3 DOTA to 1.4 for the [177Lu]Lu-1C1m-Fc conjugated to 1 DOTA. The
absorbed dose ratio tumor/liver was multiplied by 1.75 with the [177Lu]Lu-1C1m-Fc
conjugated to 1 DOTA compared to 3 DOTA.
Even if the theorical and experimental specific activity for 3 DOTA is higher than for 1
DOTA (experimentally 400 MBq/mg vs. 200 MBq/mg; data not shown), this difference
has not been taken into account in this study considering it small influence in therapeutic
applications. Indeed, regarding the professional practices in radioimmunotherapy the
amount of antibody usually injected in human is comprised between 1 and 1.5 mg/kg. If
we consider the lowest specific activity obtained with 1 DOTA, the quantity of antibody
injected will be sufficient to reach more than 8 GBq for all patients of more than 45 kg weight.
Therefore, 1C1m-Fc appeared as a very promising compound for a theranostic approach.
5. Conclusions
Antibody labeling with metal radionuclides requires the use of a bifunctional chelator
to attach radioactive metal to the protein, ideally without affecting the pharmacokinetics
of the antibody [34]. In our experiments, we have demonstrated that the number of
chelators per fusion protein antibody plays a significant role in determining successful
tumor targeting. There is thus an opportunity to further improve the biodistribution and
imaging contrast. Both absolute tumor uptake and target-to-non target ratios are important
for the selection of the best imaging agent [35]. In this study, [177Lu]Lu-1C1m-Fc conjugated
with 1 DOTA was to be the best ratio to maintain a balance between the specific activity,
immunoreactivity, and pharmacokinetic behavior and appears as an interesting candidate
for further theranostic development.
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Appendix A
Model Description
The “Kinetics” software (www.arronax-nantes.fr) allows a full description of the model
and data within a single Microsoft excel worksheet. Formulas are entered in worksheet
cells in a nearly natural mathematical language. The model involves 16 compartments (F1
to F16) representing blood, all measured tissues and an additional compartment (F2) for
the rest of the mouse body (carcass). Tissue weights (Wi), antibody immunoreactivity (IR)
and number of DOTA per antibody (DOTA) are fixed parameters. In the simultaneous
fit of all data, the different preparations are represented in different “Time interrupts”, a
feature, present in WinSAAM and used in the “Kinetics” software package, that allows the
fixed parameters to be changed.
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Figure A1. Multiple compartment mathematical model.
Transfers are assumed linear and defined in a matrix form as Ki:1*Wi*F1 (Ki:1 an
adjustable rate constant and Wi the weight of tissue i) for the transfer from blood to tissue
i and K1:i*Fi for the transfer back to blood (for compartment 2, the weight is unknown
and omitted). Elimination is set from the blood compartment (Kel). Total blood volume
cannot be identified from data because the earlier time point is 4 h. It is set to 2.2 mL
(WTB). Two additional fixed parameters are DOTA, the number of DOTA per antibody,
and IR, the immunoreactivity of the preparations. Then the effect of DOTA is described
by setting the transfer rate from blood to liver as: K5:1*DOTA*WLi*F1 and the effect of
immunoreactivity as (K3:1 + ATIR*IR)*WTu*F1 and (K15:1 + AUIR*IR)*WUt*F1 for tumor
and uterus uptake respectively (increase in uptake rate for higher immunoreactivity) and
as (K6:1-ASIR*IR)*WSp*F1 and (K10:1-ABIR*IR)*WBo*F1 for spleen and bone (increase in
uptake rate for lower immunoreactivity).
Since the tissue contents is given as % of injected activity per g (%IA/g) and each
measured tissue is represented by the content of a compartment plus an adjustable fraction
(BTu to BBl) of blood (F1). The injected activity is set to 100 and the tissue contents are
normalized by the tissue weights (WTu to WBl).
The calculations (simulations and parameter adjustment) are triggered by the user
from the Excel worksheet through a VBA macro that call advanced functions of a dynamic
linked library written in Pascal. The results are returned to the same Excel worksheet.
Reasonably close starting values for the 49 adjustable parameters and supervised fitting
are necessary.
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Figure A2. Excel data sheet example of a multi-tissue biodistribution (16 compartments) modeling.
Figure A3. Example of formulas used for modeling each measured tissue.
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Table A1. Simultaneous fit modeling.
1 DOTA 3 DOTA Simultaneous Fit 1 DOTA 3 DOTA Simultaneous Fit
Parameter Value ± SD Value ± SD Value ± SD Parameter Value ± SD Value ± SD Value ± SD
K2:1 1.01 × 10−1 ± 7.31 × 10−3 2.67 × 10−1 ± 2.92 × 10−2 1.08 × 10−1 ± 1.65 × 10−2 BTu 3.68 × 10−2 ± 1.98 × 10−3 1.41 × 10−2 ± 1.88 × 10−3 4.74 × 10−3 ± 3.21 × 10−3
K1:2 7.65 × 10−2 ± 4.28 × 10−3 2.76 × 10−1 ± 3.28 × 10−2 8.11 × 10−2 ± 1.01 × 10−2 BLu 2.75 × 10−2 ± 1.25 × 10−3 2.75 × 10−2 ± 1.54 × 10−3 2.38 × 10−2 ± 3.03 × 10−3
K3:1 1.63 × 10−2 ± 7.06 × 10−4 2.37 × 10−2 ± 1.30 × 10−3 9.27 × 10−3 ± 2.87 × 10−3 BLi 2.49 × 10−1 ± 8.67 × 10−3 2.75 × 10−1 ± 1.46 × 10−2 1.83 × 10−1 ± 2.05 × 10−2
K1:3 1.07 × 10−2 ± 6.96 × 10−4 2.31 × 10−2 ± 1.20 × 10−3 2.33 × 10−2 ± 2.44 × 10−3 BSp 1.65 × 10−2 ± 7.39 × 10−4 1.68 × 10−2 ± 9.29 × 10−4 1.51 × 10−2 ± 1.73 × 10−3
K4:1 3.85 × 10−3 ± 4.44 × 10−4 3.32 × 10−3 ± 7.04 × 10−4 7.97 × 10−3 ± 1.87 × 10−3 BKi 4.85 × 10−2 ± 2.12 × 10−3 5.38 × 10−2 ± 2.78 × 10−3 4.93 × 10−2 ± 5.31 × 10−3
K1:4 2.06 × 10−2 ± 2.24 × 10−3 3.03 × 10−2 ± 5.00 × 10−3 3.98 × 10−2 ± 8.80 × 10−3 BHe 1.43 × 10−2 ± 6.17 × 10−4 1.54 × 10−2 ± 8.02 × 10−4 1.36 × 10−2 ± 1.63 × 10−3
K5:1 3.18 × 10−3 ± 1.02 × 10−4 9.90 × 10−3 ± 6.29 × 10−4 7.62 × 10−3 ± 5.80 × 10−4 BMu 2.07 × 10−3 ± 1.53 × 10−4 2.62 × 10−3 ± 1.96 × 10−4 2.23 × 10−3 ± 3.70 × 10−4
K1:5 0.00 ± NA 1.25 × 10−2 ± 9.88 × 10−4 1.76 × 10−2 ± 1.94 × 10−3 BBo 2.35 × 10−3 ± 1.16 × 10−4 2.99 × 10−3 ± 1.53 × 10−4 2.49 × 10−3 ± 2.90 × 10−4
K6:1 4.20 × 10−3 ± 3.06 × 10−4 7.83 × 10−3 ± 6.85 × 10−4 6.36 × 10−2 ± 6.77 × 10−3 BSt 9.96 × 10−3 ± 5.69 × 10−4 8.55 × 10−3 ± 6.54 × 10−4 8.84 × 10−3 ± 1.34 × 10−3
K1:6 8.50 × 10−3 ± 9.92 × 10−4 1.95 × 10−2 ± 1.70 × 10−3 1.77 × 10−2 ± 2.60 × 10−3 BSi 6.85 × 10−2 ± 3.37 × 10−3 7.03 × 10−2 ± 4.05 × 10−3 6.69 × 10−2 ± 8.29 × 10−3
K7:1 3.68 × 10−3 ± 2.50 × 10−4 3.54 × 10−3 ± 3.78 × 10−4 4.91 × 10−3 ± 6.68 × 10−4 BCo 4.14 × 10−2 ± 2.00 × 10−3 4.14 × 10−2 ± 2.41 × 10−3 3.74 × 10−2 ± 4.94 × 10−3
K1:7 4.72 × 10−3 ± 8.76 × 10−4 1.50 × 10−2 ± 1.66 × 10−3 1.32 × 10−2 ± 2.45 × 10−3 BOv 7.59 × 10−3 ± 2.54 × 10−4 2.48 × 10−3 ± 2.32 × 10−4 3.33 × 10−3 ± 5.24 × 10−4
K8:1 1.03 × 10−3 ± 2.24 × 10−4 1.37 × 10−3 ± 3.52 × 10−4 3.28 × 10−3 ± 1.09 × 10−3 BUt 2.65 × 10−2 ± 1.14 × 10−3 1.08 × 10−2 ± 7.19 × 10−4 1.17 × 10−2 ± 1.57 × 10−3
K1:8 1.58 × 10−2 ± 3.35 × 10−3 2.42 × 10−2 ± 4.96 × 10−3 3.68 × 10−2 ± 1.12 × 10−2 BBl 7.88 × 10−4 ± 5.44 × 10−5 5.88 × 10−4 ± 6.41 × 10−5 6.32 × 10−4 ± 1.15 × 10−4
K9:1 1.53 × 10−3 ± 1.00 × 10−4 9.49 × 10−4 ± 1.01 × 10−4 1.46 × 10−3 ± 2.07 × 10−4 Kel 3.51 × 10−2 ± 5.48 × 10−4 4.23 × 10−2 ± 6.64 × 10−4 4.53 × 10−2 ± 1.54 × 10−3
K1:9 1.07 × 10−2 ± 1.08 × 10−3 1.53 × 10−2 ± 1.85 × 10−3 1.49 × 10−2 ± 2.92 × 10−3 ATIR 2.57 × 10−2 ± 3.74 × 10−3
K10:1 1.51 × 10−3 ± 1.33 × 10−4 1.14 × 10−3 ± 1.32 × 10−4 1.09 × 10−2 ± 1.58 × 10−3 ASIR 6.37 × 10−2 ± 7.45 × 10−3
K1:10 4.42 × 10−3 ± 1.09 × 10−3 6.08 × 10−3 ± 1.45 × 10−3 7.62 × 10−3 ± 2.48 × 10−3 ABIR 1.05 × 10−2 ± 1.75 × 10−3
K11:1 1.26 × 10−3 ± 1.04 × 10−4 9.95 × 10−4 ± 1.02 × 10−4 1.78 × 10−3 ± 2.62 × 10−4 AUIR 1.68 × 10−3 ± 2.31 × 10−3
K1:11 9.67 × 10−3 ± 1.26 × 10−3 1.46 × 10−2 ± 1.65 × 10−3 1.80 × 10−2 ± 3.28 × 10−3
K12:1 9.21 × 10−4 ± 9.60 × 10−5 8.57 × 10−4 ± 1.10 × 10−4 1.49 × 10−3 ± 2.57 × 10−4
K1:12 6.19 × 10−3 ± 1.36 × 10−3 9.86 × 10−3 ± 1.75 × 10−3 1.30 × 10−2 ± 3.08 × 10−3
K13:1 7.66 × 10−4 ± 7.69 × 10−5 8.51 × 10−4 ± 1.06 × 10−4 1.72 × 10−3 ± 2.76 × 10−4
K1:13 2.28 × 10−3 ± 1.21 × 10−3 1.02 × 10−2 ± 1.73 × 10−3 1.52 × 10−2 ± 3.24 × 10−3
K14:1 1.49 × 10−3 ± 6.42 × 10−5 3.81 × 10−3 ± 2.60 × 10−4 4.80 × 10−3 ± 5.90 × 10−4
K1:14 0.00 ± NA 1.68 × 10−2 ± 1.25 × 10−3 1.57 × 10−2 ± 2.50 × 10−3
K15:1 6.36 × 10−3 ± 3.76 × 10−4 9.85 × 10−3 ± 5.63 × 10−4 9.90 × 10−3 ± 1.87 × 10−3
K1:15 2.98 × 10−3 ± 7.11 × 10−4 1.27 × 10−2 ± 9.37 × 10−4 1.01 × 10−2 ± 1.51 × 10−3
K16:1 5.86 × 10−3 ± 2.74 × 10−4 6.82 × 10−3 ± 4.16 × 10−4 6.38 × 10−3 ± 5.53 × 10−4
K1:16 8.19 × 10−3 ± 7.14 × 10−4 1.75 × 10−2 ± 1.20 × 10−3 1.10 × 10−2 ± 1.64 × 10−3
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